Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronary Artery Bypass Graft Surgery Patients Clear all
Completed Phase 3 Interventional Results available

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients

NCT02192502
View directory record Official record
Conditions
Postoperative Kidney Injury
Interventions
human albumin 5%, HES 130/0.4 (Voluven)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 85 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

NCT01245634
View directory record Official record
Conditions
Coronary Heart Disease, Graft Occlusion, Vascular
Interventions
Placebo, RO4905417
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 85 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Not applicable Interventional Results available

Transitional Rehabilitation in CABG Patients

NCT03892460
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Bypass Graft Surgery
Interventions
neuromuscular electrical stimulation
Device
Lead sponsor
University of Vermont
Other
Eligibility
50 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 3 Interventional

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

NCT00048308
View directory record Official record
Conditions
Cardio-pulmonary Bypass, Coronary Artery Bypass Graft
Interventions
pexelizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
168
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 3 Interventional

Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures

NCT00042081
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CGT003 (E2F Duplex Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
154
States / cities
Birmingham, Alabama • Daly City, California • Los Angeles, California + 89 more
Source: ClinicalTrials.gov public record
Updated May 5, 2006 · Synced Oct 4, 2026, 5:34 PM EDT
Terminated No phase listed Observational

LifeVest Post-CABG Registry

NCT01448005
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Fibrillation, Ventricular Tachycardia, Ventricular Dysfunction, Myocardial Ischemia
Interventions
wearable defibrillator (LifeVest)
Device
Lead sponsor
Zoll Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Sacramento, California • Atlanta, Georgia • Takoma Park, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

NCT00402506
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
Interventions
(MC-1) Pyridoxal 5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

NCT00079508
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Oct 4, 2026, 5:34 PM EDT
Active, not recruiting No phase listed Observational

Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery

NCT07009340
View directory record Official record
Conditions
Post-discharge Outcomes
Interventions
Not listed
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Huntsville, Alabama • Fort Wayne, Indiana • Midland, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 4 Interventional Results available

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

NCT03939923
View directory record Official record
Conditions
Surgery, Coronary Artery Disease
Interventions
Rocuronium, Neostigmine, Glycopyrrolate, Sugammadex
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 4, 2026, 5:34 PM EDT
Completed No phase listed Observational

The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients

NCT00226265
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Heart Diseases, Heart Valve Diseases
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 4, 2026, 5:34 PM EDT
Not listed Phase 3 Interventional

Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery

NCT01500369
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
sphygmomanometer cuff inflations, standard of care
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of BoneSeal® on Bone Hemostats in Patients Undergoing Cardiothoracic Surgery

NCT03085017
View directory record Official record
Conditions
Coronary Artery Bypass Grafting
Interventions
BoneSeal, Ostene
Device
Lead sponsor
Loma Linda University
Other
Eligibility
45 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients

NCT00576394
View directory record Official record
Conditions
Glycemic Control
Interventions
IV Insulin drip, Insulin
Drug
Lead sponsor
American Heart Association
Other
Eligibility
18 Years to 90 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 4, 2026, 5:34 PM EDT
Recruiting Early Phase 1 Interventional

Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone

NCT06063538
View directory record Official record
Conditions
Atrial Fibrillation, Post-Op Complication
Interventions
CardiaMend in Combination with Amiodarone
Combination Product
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 4, 2026, 5:34 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery

NCT07646210
View directory record Official record
Conditions
Advanced Heart Failure, Ischemic Heart Failure
Interventions
HiCM-188 Cells
Drug
Lead sponsor
HELP Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Parasternal Nerve Block in Cardiac Patients

NCT01826851
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Postoperative
Interventions
Exparel, Placebo
Drug
Lead sponsor
Peter A Knight
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 4 Interventional Results available

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

NCT01863134
View directory record Official record
Conditions
Non ST Elevation Myocardial Infarction
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
Medical University of Silesia
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 4, 2026, 5:34 PM EDT
Not yet recruiting Phase 3 Interventional

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

NCT07357675
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
Interventions
EA-230 90mg/kg/hour, Placebo
Drug
Lead sponsor
EBI Anti Sepsis BV
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 4, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Acceptance and Commitment Therapy for Patients Undergoing Coronary Artery Bypass Graft Surgery

NCT06207318
View directory record Official record
Conditions
Coronary Artery Disease, Vascularization
Interventions
Acceptance and commitment therapy
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 4, 2026, 5:34 PM EDT
Completed No phase listed Observational

Effects of a Hybrid Model of Cardiac Rehabilitation on Patient Outcomes

NCT06030115
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Graft CABG, Stent, Valve Replacement
Interventions
Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)
Other
Lead sponsor
Good Shepherd Integrated Healthcare Systems
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 4, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

Vitamin C in Cardiac Surgery Patients

NCT03123107
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery
Interventions
Ascorbic Acid
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
21 Years to 79 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 4, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

The Relationship Between Blood Flow Readings During Surgery and How Well the Graft Stays Open and How Patients Recover Afterward in Coronary Artery Bypass Graft Surgery

NCT07485738
View directory record Official record
Conditions
CABG Graft Integrity, CABG, Blood Flow, Transit-time Flow Measurement, Heart Disease
Interventions
Transit-Time Flow Measurement (TTFM)
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 4, 2026, 5:34 PM EDT
Not yet recruiting Phase 2 Interventional

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

NCT07118449
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
XC001, A195/placebo
Drug
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 4, 2026, 5:34 PM EDT